文献速递药物不良反应与药物警戒

健康成人使用大麻二酚与肝功能异常:I期临床试验结果

Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial.
PubMed 文献 · Clin Pharmacol Ther · 2020-11-21

7名(44%)参与者出现峰值血清ALT超过正常上限(ULN),其中5名(31%)超过5×ULN,符合药物性肝损伤的国际共识标准。转氨酶升高与基线特征、CYP2C19基因型或CBD血浆浓度无相关性,所有ALT升高均在首次暴露后2-4周内开始。

要点

  • 健康成人每日使用CBD 1,500 mg约3.5周,44%出现ALT超过ULN。
  • 31%参与者ALT超过5×ULN,符合药物性肝损伤国际共识标准。
  • 转氨酶升高与基线特征、CYP2C19基因型或CBD血浆浓度无相关性。

核心结论

  • 健康成人使用CBD可能出现血清ALT升高,符合药物性肝损伤表现。
  • 鉴于个体易感性差异,临床医生应警惕CBD的这一潜在效应。

研究设计与样本

  • 每日给予CBD 1,500 mg约3.5周,研究其对CYP1A2活性的影响。

主要发现

  • 7名(44%)参与者峰值血清ALT超过ULN。
  • 5名(31%)参与者ALT超过5×ULN,符合药物性肝损伤国际共识标准。
  • 转氨酶升高与基线特征、CYP2C19基因型或CBD血浆浓度无相关性。
  • 所有超过ULN的ALT升高均在首次暴露于CBD后2-4周内开始。
  • 6名ALT升高参与者中止方案,部分出现肝炎或超敏反应相关症状。

临床怎么用

  • 临床医生应警惕健康成人使用CBD可能导致血清ALT升高。
  • 使用CBD期间应考虑监测肝功能,尤其在前4周内。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Liver safety concerns were raised in randomized controlled trials of cannabidiol (CBD) in patients with Lennox-Gastaut and Dravet syndromes, but the relevance of these concerns to healthy adults consuming CBD is unclear. The objective of this manuscript is to report on liver safety findings from healthy adults who received therapeutic daily doses of CBD for ~ 3.5 weeks and to investigate any correlation between transaminase elevations and baseline characteristics, pharmacogenetic, and pharmacokinetic data. Sixteen healthy adults were enrolled in a phase I, open-label, fixed single-sequence drug-drug interaction trial to investigate the effect of repeated dose administration of CBD (1,500 mg/day) on cytochrome P450 (CYP) 1A2 activity. Seven (44%) participants experienced peak serum alanine aminotransferase (ALT) values greater than the upper limit of normal (ULN). For five (31%) participants, the value exceeded 5 × ULN, therefore meeting the international consensus criteria for drug-induced liver injury. There was no correlation between transaminase elevations and baseline characteristics, CYP2C19 genotype, or CBD plasma concentrations. All ALT elevations above the ULN began within 2-4 weeks of initial exposure to CBD. Among the six participants with ALT elevations who were discontinued from the protocol, some had symptoms consistent with hepatitis or hypersensitivity. We conclude that healthy adults consuming CBD may experience elevations in serum ALT consistent with drug-induced liver injury. Given the demonstrated interindividual variation in susceptibility, clinicians should be alert to this potential effect from CBD, which is increasingly available in various nonprescription forms and doses to consumers.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Watkins PB, Church RJ, Li J, et al. Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. Clin Pharmacol Ther. 2020. PMID: 33022751. doi:10.1002/cpt.2071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。